Program
selinexor
Also written as “Selinexor”, “Selinexor (combination therapy)” and “Selinexor 40 mg”.
Its studies are mostly in Multiple Myeloma · Lymphoma, Large B-Cell, Diffuse · Primary Myelofibrosis · Endometrial Neoplasms · Glioblastoma, led by 6 companies.
Drug pageSelinexor: every studyMany companies study it; this page follows only the 40 they lead. All 163 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Karyopharm Therapeutics | 316 open or running | phase 3since Oct 13, 2015 | May 16, 2012 | Dec 2026phase 3 · NCT04442022 |
| Antengeneits history only | 40 open or running | phase 2since Apr 30, 2019 | Apr 30, 2019 | none ahead |
| Oncotherapeuticsits history only | 22 open or running | phase 1since Aug 12, 2020 | Aug 12, 2020 | Apr 1, 2027phase 1 · NCT06225310 |
| AbbVieits history only | 11 open or running | phase 3since Nov 28, 2023 | Nov 28, 2023 | Dec 2027phase 3 · NCT06158841 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Aug 13, 2025 | Aug 13, 2025 | Dec 2027phase 3 · NCT07138209 |
| Sarah Cannon Research Instituteits history only | 11 open or running | phase 2since Mar 1, 2021 | Mar 1, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Karyopharm Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since May 16, 2012.
- Dec 2, 2015Phase 2 study in Multiple MyelomaNCT02628704 · United States
- Apr 7, 2017Phase 3 study in Multiple MyelomaNCT03110562 · 402 enrolled · United States, Australia, Austria and more
- May 18, 2018Phase 3 study in Endometrial NeoplasmsNCT03555422 · 263 enrolled · United States, Belgium, Canada and more
- Feb 3, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04256707 · 80 enrolled · Israel
- Apr 14, 20202 phase 2 studies in Coronavirus InfectionsNCT04349098, NCT04355676
- Jun 1, 20202 phase 2 studiesNCT04421378, NCT04414475
- Jun 10, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04442022 · 501 enrolled · United States, China, Israel and more
- Sep 9, 2020Phase 2 study in Primary MyelofibrosisNCT04562870 · 112 enrolled · United States, China, France and more
- Sep 14, 2020Phase 3 study in Primary MyelofibrosisNCT04562389 · 353 enrolled · United States, Australia, Belgium and more
- Feb 22, 2021Phase 2 study in MelanomaNCT04768881 · 15 enrolled · United States
- Apr 17, 2021Phase 2 study in Colorectal NeoplasmsNCT04854434 · 13 enrolled · United States
- Nov 3, 2022Phase 3 study in Endometrial NeoplasmsNCT05611931 · 257 enrolled · United States, Australia, Belgium and more
- Jul 24, 2023Phase 2 study in Primary MyelofibrosisNCT05980806 · 58 planned · United States, Belgium, Bulgaria and more
- Nov 19, 2026Phase 2 study terminatedStudy stoppedNCT02227251 · “Terminated in alignment with FDA agreement to withdraw accelerated approval of DLBCL indication. This withdrawal is not due to safety con…”
Ahead
- Dec 2026Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT04442022
- Jun 2027Primary completion: phase 2 study in Primary MyelofibrosisNCT05980806
- Jan 2028Primary completion: phase 2 study in Multiple MyelomaNCT04414475
TargetBeta
“An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), ”NCIt, by rule
“Exportin-1 inhibitor”ChEMBL 37, by rule
Other programs on XPO1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQB3107 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 31 Karyopharm Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05980806Primary Myelofibrosis · United States, Belgium, Bulgaria and more | 2 | Recruiting | Jun 2027 | 58 |
| NCT05611931Endometrial Neoplasms · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 22, 2026 | 257 |
| NCT04854434Colorectal Neoplasms · United States | 2 | Terminated | Jun 24, 2022 | 13 |
| NCT04768881Melanoma · United States | 2 | Terminated | Sep 22, 2023 | 15 |
| NCT04562389Primary Myelofibrosis · United States, Australia, Belgium and more | 3 | Active, not recruiting | Feb 20, 2026 | 353 |
| NCT04562870Primary Myelofibrosis · United States, China, France and more | 2 | Active, not recruiting | Sep 2026 | 112 |
| NCT04442022Lymphoma, Large B-Cell, Diffuse · United States, China, Israel and more | 3 | Active, not recruiting | Dec 2026 | 501 |
| NCT04414475Multiple Myeloma · Greece, Israel | 2 | Recruiting | Jan 2028 | 127 |
| NCT04421378Glioblastoma · United States, Canada | 2 | Terminated | Jul 3, 2023 | 74 |
| NCT04355676Coronavirus Infections | 2 | Withdrawn | Aug 30, 2020 | 0 |
| NCT04349098Coronavirus Infections · United States, Austria, France and more | 2 | Completed | Oct 5, 2020 | 190 |
| NCT04256707Carcinoma, Non-Small-Cell Lung · Israel | 2 | Completed | Jul 31, 2024 | 80 |
| NCT03555422Endometrial Neoplasms · United States, Belgium, Canada and more | 3 | Completed | Jan 22, 2022 | 263 |
| NCT03110562Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Feb 18, 2020 | 402 |
| NCT02628704Multiple Myeloma · United States | 2 | Withdrawn | Jun 2017 | 0 |
| NCT02606461Liposarcoma · United States, Belgium, Canada and more | 3 | Completed | Oct 28, 2020 | 342 |
| NCT02431351Myelodysplastic Syndromes | 2 | Withdrawn | Dec 2017 | 0 |
| NCT02389543Multiple Myeloma | 2 | Withdrawn | Jan 2018 | 0 |
| NCT02367690Diabetic Foot · New Zealand | 2 | Withdrawn | May 2015 | 0 |
| NCT02336815Multiple Myeloma · United States, Austria, Belgium and more | 2 | Completed | Jul 26, 2019 | 202 |
| NCT02314247Lymphoma, T-Cell, Peripheral · Australia, Singapore | 2 | Terminated | Jan 2016 | 16 |
| NCT02227251Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more | 2 | Terminated | Jun 2, 2026 | 279 |
| NCT02213133Carcinoma, Squamous Cell · United States, Canada | 2 | Terminated | Dec 10, 2015 | 45 |
| NCT02146833Prostatic Neoplasms · United States | 2 | Terminated | Apr 1, 2016 | 20 |
| NCT02138786Richter's Transformation · United States, Germany, Poland and more | 2 | Terminated | Aug 31, 2016 | 27 |
| NCT02088541Leukemia, Myeloid, Acute · United States, Canada, Denmark and more | 2 | Completed | Jan 8, 2018 | 317 |
| NCT02025985Ovarian Neoplasms · Belgium, Denmark | 2 | Completed | Jan 24, 2017 | 116 |
| NCT01986348Glioblastoma · United States, Denmark, Netherlands | 2 | Terminated | Jan 23, 2020 | 76 |
| NCT01896505Sarcoma · United States, Canada | 1 | Completed | Oct 21, 2016 | 54 |
| NCT01607905Carcinoma, Squamous Cell · United States, Canada, Denmark | 1 | Completed | Mar 15, 2016 | 192 |
| NCT01607892Hematologic Neoplasms · United States, Canada, Denmark | 1 | Completed | Oct 13, 2015 | 286 |
How it is read
Names in the registry
- “Selinexor”, 32 entries
- “Selinexor (combination therapy)”, 3 entries
- “Selinexor 40 mg”, 2 entries
- “Selinexor 60 mg”, 2 entries
- “ATG-010”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 11 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Primary Myelofibrosis, 3 studies
- Endometrial Neoplasms, 2 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.